Add-on radioiodine during long-term BRAF/MEK inhibition in patients with RAI-refractory thyroid cancers: a reasonable option?

Dual modulation of the MAPK pathway with BRAF (e.g., dabrafenib) and MEK (e.g., trametinib) inhibitors has the potential to re-establish radioiodine (RAI) sensitivity in BRAF-mutated RAI-refractory (RAI-R)-differentiated thyroid carcinoma (DTC) cells. Here we showed that (1) double BRAF/MEK inhibiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Montes de Jesus, Filipe Miguel, Espeli, Vittoria, Paone, Gaetano, Giovanella, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403389/
https://www.ncbi.nlm.nih.gov/pubmed/37191938
http://dx.doi.org/10.1007/s12020-023-03388-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403389/
https://www.ncbi.nlm.nih.gov/pubmed/37191938
http://dx.doi.org/10.1007/s12020-023-03388-6

Ejemplares similares